In Brief: J&J/Ostex
This article was originally published in The Gray Sheet
J&J/Ostex: Johnson & Johnson Clinical Diagnostics gains co-exclusive ten-year license "to adapt and distribute" Ostex's first product, the Osteomark bone resorption test, for use on J&J's analyzers. The license applies worldwide except for Japan. Under a separate agreement, J&J also will distribute Ostex-manufactured Osteomark test kits in "several world markets." Osteomark, cleared by FDA on May 8, is a urine test designed to diagnose patients who are losing bone mass at a high rate...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.